Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$5.58 -3.5%	$5.11	$3.55 ▼ $11.16	$429.74M	1.13	2.83 million shs	2.11 million shs
CGEM Cullinan Therapeutics	$7.50 +3.6%	$8.01	$6.85 ▼ $24.99	$442.61M	-0.07	586,184 shs	440,232 shs
CGEN Compugen	$1.39 +1.5%	$1.43	$1.13 ▼ $2.66	$124.04M	2.61	390,651 shs	345,541 shs
ETON Eton Pharmaceuticals	$18.93 -3.9%	$14.82	$3.18 ▼ $21.48	$507.67M	1.22	191,500 shs	400,040 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+1.40%	-0.45%	+27.59%	-9.26%	-34.84%
CGEM Cullinan Therapeutics	+1.54%	-7.02%	-7.18%	-24.03%	-72.90%
CGEN Compugen	+4.58%	+6.20%	-0.72%	-38.29%	-38.01%
ETON Eton Pharmaceuticals	+15.07%	+13.98%	+38.83%	+19.98%	+439.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.3559 of 5 stars	3.5	1.0	2.1	3.3	0.6
CGEM Cullinan Therapeutics	2.3745 of 5 stars	3.5	2.0	2.0	2.5	0.6
CGEN Compugen	1.8362 of 5 stars	3.5	4.0	1.9	0.0	0.0
ETON Eton Pharmaceuticals	2.4819 of 5 stars	3.5	3.0	3.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	3.00	Buy	$20.20	262.01% Upside
CGEM Cullinan Therapeutics	3.00	Buy	$32.00	326.67% Upside
CGEN Compugen	3.00	Buy	$4.00	187.77% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.00	53.20% Upside

Current Analyst Ratings Breakdown

Latest CGEN, CGEM, ETON, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/14/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$26.00 ➝ $28.00
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
4/16/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
4/3/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/19/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $26.00
3/19/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $24.00
3/19/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
3/18/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/14/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/7/2025	CGEM Cullinan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$38.00 ➝ $35.00

(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	21,486.91	N/A	N/A	$2.75 per share	2.03
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.61 per share	N/A
CGEN Compugen	$27.86M	4.45	N/A	N/A	$0.73 per share	1.90
ETON Eton Pharmaceuticals	$39.01M	13.01	$0.00 per share	4,502.79	$0.60 per share	31.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.34	N/A	N/A	N/A	-199,076.92%	-55.81%	-50.60%	N/A
CGEM Cullinan Therapeutics	-$153.16M	-$2.91	N/A	N/A	N/A	N/A	-26.54%	-25.32%	N/A
CGEN Compugen	-$18.75M	-$0.16	69.50	N/A	N/A	2.67%	2.62%	1.36%	5/19/2025 (Estimated)
ETON Eton Pharmaceuticals	-$940K	-$0.15	N/A	37.86	N/A	-15.81%	-36.29%	-16.84%	N/A

Latest CGEN, CGEM, ETON, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.80	N/A	N/A	N/A	N/A	N/A
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	N/A	N/A	N/A	$3.70 million	N/A
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
3/18/2025	Q4 2024	ETON Eton Pharmaceuticals	-$0.02	-$0.02	N/A	-$0.02	$10.53 million	$11.65 million
3/4/2025	Q4 2024	CGEN Compugen	$0.07	-$0.07	-$0.14	-$0.07	$17.47 million	$1.47 million
2/27/2025	Q4 2024	ALT Altimmune	-$0.34	-$0.33	+$0.01	-$0.33	$0.00 million	$0.01 million
2/27/2025	Q4 2024	CGEM Cullinan Therapeutics	-$0.75	-$0.73	+$0.02	-$0.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	16.87	16.87
CGEM Cullinan Therapeutics	N/A	24.46	24.46
CGEN Compugen	N/A	4.14	4.14
ETON Eton Pharmaceuticals	N/A	1.51	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
CGEM Cullinan Therapeutics	86.31%
CGEN Compugen	12.22%
ETON Eton Pharmaceuticals	27.86%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
CGEM Cullinan Therapeutics	7.16%
CGEN Compugen	9.50%
ETON Eton Pharmaceuticals	16.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	77.01 million	68.21 million	Optionable
CGEM Cullinan Therapeutics	30	59.02 million	54.69 million	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.17 million	Optionable

CGEN, CGEM, ETON, and ALT Headlines

Recent News About These Companies

Parkman Healthcare Partners LLC Grows Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

May 16 at 8:33 AM | marketbeat.com

Eton Pharmaceuticals (NASDAQ:ETON) Hits New 1-Year High Following Analyst Upgrade

May 16 at 1:17 AM | americanbankingnews.com

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2025 Earnings Call Transcript

May 15 at 10:35 AM | msn.com

Mink Brook Asset Management LLC Takes $6.07 Million Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

May 15 at 7:07 AM | marketbeat.com

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

May 14 at 4:30 PM | globenewswire.com

A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts

May 14 at 2:55 PM | benzinga.com

Q1 2025 Eton Pharmaceuticals Inc Earnings Call

May 14 at 9:54 AM | finance.yahoo.com

Eton outlines path to $100M near-term revenue with ET-400 launch and Increlex growth

May 13 at 11:52 PM | msn.com

Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript

May 13 at 11:36 PM | seekingalpha.com

Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates

May 13 at 6:20 PM | zacks.com

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

May 13 at 4:01 PM | globenewswire.com

Zevra Therapeutics's Earnings Outlook

May 12, 2025 | benzinga.com

A Look Ahead: Eton Pharmaceuticals's Earnings Forecast

May 12, 2025 | benzinga.com

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Bought by Schonfeld Strategic Advisors LLC

May 10, 2025 | marketbeat.com

Envestnet Asset Management Inc. Invests $236,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

May 10, 2025 | marketbeat.com

Barclays PLC Takes Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

May 9, 2025 | marketbeat.com

7EYPT : A Peek at EyePoint Pharmaceuticals's Future Earnings

May 6, 2025 | benzinga.com

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Purchased by Marshall Wace LLP

May 5, 2025 | marketbeat.com

683 Capital Management LLC Purchases New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

May 4, 2025 | marketbeat.com

Eton Pharmaceuticals (ETON) to Release Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Q1 EPS Estimate for Eton Pharmaceuticals Lifted by Analyst

May 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN, CGEM, ETON, and ALT Company Descriptions

Altimmune NASDAQ:ALT

$5.58 -0.20 (-3.46%)

Closing price 04:00 PM Eastern

Extended Trading

$5.48 -0.10 (-1.79%)

As of 07:55 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Cullinan Therapeutics NASDAQ:CGEM

$7.50 +0.26 (+3.59%)

Closing price 04:00 PM Eastern

Extended Trading

$7.69 +0.19 (+2.52%)

As of 06:47 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Compugen NASDAQ:CGEN

$1.39 +0.02 (+1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$1.39 0.00 (0.00%)

As of 07:51 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Eton Pharmaceuticals NASDAQ:ETON

$18.93 -0.77 (-3.91%)

Closing price 04:00 PM Eastern

Extended Trading

$18.94 +0.02 (+0.08%)

As of 07:59 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time